Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
我们正在追踪 WuXi Biologics/药明生物 的市场扩张
新增 业务布局 活动 — 刚出现 9 个新信号。
WuXi Biologics/药明生物 的国际扩张与竞争对手的对比情况
WuXi Biologics/药明生物你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 WuXi Biologics/药明生物你 | 0 | 0 | — | 0 | 0 |
Talent Acquisition Specialist
查看职位Tuas, West Region, Singapore · 昨天
Manufacturing Manager/ Senior Manager, Lyophilization Drug Product Operations
查看职位Singapore, Singapore · 昨天
Supply Chain Senior Manager (Import & Export Biomaterial)
查看职位Singapore, Singapore · 前天
药明生物宣布其位于上海的药品设施15获得GMP认证,这是其全球第18个运营药品设施,配备先进无菌灌装能力,支持临床阶段生物制剂项目。
药明生物发布2025年可持续发展报告,强调对医疗公平、治理透明度、员工赋能、气候行动及绿色CRDMO解决方案的承诺。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 WuXi Biologics/药明生物 的业务、市场和增长信号的快速解答。
